Purpose of this Study
We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are diagnosed with unresectable colorectal cancer</li>
<li>Have metastases to the liver</li>
<li>Have received a 3-6 month course of previous first-line chemotherapy</li>
<li>Have not received radiation therapy directed toward the liver</li></ul>
For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.
<li>Are diagnosed with unresectable colorectal cancer</li>
<li>Have metastases to the liver</li>
<li>Have received a 3-6 month course of previous first-line chemotherapy</li>
<li>Have not received radiation therapy directed toward the liver</li></ul>
For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:<ul>
<li>Group 1 will get will get chemotherapy that's given in the traditional manner and directly into the hepatic artery</li>
<li>Group 2 will get will get chemotherapy that's given in the traditional manner only</li></ul>
<li>Group 1 will get will get chemotherapy that's given in the traditional manner and directly into the hepatic artery</li>
<li>Group 2 will get will get chemotherapy that's given in the traditional manner only</li></ul>
Study Details
Full Title
EA2222: A Randomized Phase III Study of Systemic Therapy With or Without Hepatic arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial
Principal Investigator
Hope
Uronis
Protocol Number
PRO00114675
NCT ID
NCT05863195
Phase
III
Enrollment Status
Open to Enrollment